Mile Brujic, OD, FAAO, discusses his new research being presented at the Southeastern Educational Congress of Optometry 2025 meeting concerning dry eye treatment.
Mile Brujic, OD, FAAO, a partner at Premier Vision Group, discussed new research on dry eye being presented at the Southeastern Educational Congress of Optometry (SECO) 2025 meeting held from February 27 to March 2, 2025, in Atlanta, Georgia. He also discussed how light therapy can be used in various eye conditions effectively.
This transcript has been lightly edited for clarity; captions were auto-generated.
Transcript
Can you explain what research you are presenting at SECO?
I'm here at SECO presenting a paper, and it's some interesting data. It was a case series on patients who were being treated for dry eye with a variety of different strategies. And 1 of the things that I had them on, in addition to usually pharmaceuticals and other advanced procedures, was I had them on intracanalicular, dissolvable plugs that usually last about 6 months.
Well, there's now a new, novel gel that's made of sodium hyaluronate that we can actually fill the lacrimal system with, and in doing so, you get a more full fill. I was curious to see, is there going to be any clinical difference in these patients who have traditionally had the rod-type intracanalicular plugs versus the gel? What we found was surprising. On these 3 patients that I'm reporting on, their corneal staining improved dramatically. Their speed scores improved, and interestingly, a lot of their InflammaDry scores improved as well.
Key takeaways from the poster would be [that] intracanalicular, dissolvable sodium hyaluronate gel is certainly becoming impactful and more important in our clinical practices, and I think as a standalone or also to supplement our dry efforts, I think it's just going to improve patients' lifestyles.
How can light therapy help patients manage their eye conditions?
When we talk about light therapy and eye care, it's evolved tremendously. We used to think it's making sure we protect our eyes from UV exposure. Certainly, that's one ramification to light. But we've now leveraged and harnessed the power of light, not only to refract patients, but also to help them with other conditions. The 2 biggest things that we have in eye care right now are low-level light therapy and intense pulse light therapy. And both of these leverage different wavelengths for patient care. What we find is it helps patients with ocular rosacea or standard dry eye, secondary to meibomian gland dysfunction, and gives them the ability to restore some normalcy.
The way we treat them right now is, for low light level therapy, it's a session of 6 sessions where they sit behind a high-powered low light level therapy for 15 minutes at a time, separated by 1 week. For [intense pulse light], it's 4 sessions separated by 2 weeks apart with intense pulsed light on the surface of the eye. The good news is, it works.
The bad news is, from a patient's perspective, they are required to pay those costs. It's a different conversation when somebody doesn't have coverage for this and the patient actually has to either do 1 of 2 things: look at their own funds to determine how they're actually going to pay for it, or decide against treatment, which is always an unfortunate predicament when we have that in our offices, when we know it'll help patients.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More